RATIONALE: To acquire long-term safety data on IGHy (immunoglobulin infusion 10% with recombinant human hyaluronidase [rHuPH20]) a post-authorization safety study was initiated in patients with primary immunodeficiency diseases (PIDD). METHODS: This ongoing, prospective, non-interventional, open-label, uncontrolled, multicenter study includes patients aged > _16 years with PIDD receiving IGHy in the United States. Patients are followed according to standard clinical practice and their treatment regimen is at the discretion of the treating physician. All adverse events (AEs) are assessed based on seriousness, severity, and causal relatedness to IGHy. The presence of antirHuPH20 antibody is evaluated on a voluntary basis. RESULTS: As of August 2017, 175 patients were enrolled at 26 US study sites. Two patients had discontinued due to an AE. There were no treatment-related serious AEs (SAEs). Fifteen (8.6%) patients reported 22 unrelated SAEs (14 severe, 7 moderate, and 1 mild). Evolve Biologics, Mississauga, Canada. RATIONALE: PlasmaCap IG is a novel immunoglobulin manufactured through affinity chromatography (PlasmaCap EBAä) eliminating the use of ethanol precipitation, resulting in a high purity IgG. We present interim safety data from the adult portion of the Phase III multi-center study of PlasmaCap IG in PIDD patients. METHODS: To date, 48 adult PIDD subjects have been enrolled. Subjects, aged 17 to 70 years, received PlasmaCap IG therapy (300-900 mg/kg every 3-4 weeks) for > _3 months before enrollment and had screening serum immunoglobulin G trough levels of >500 mg/dL. Subjects received the same dosing from the time of screening. RESULTS: Subjects received approximately 17 PlasmaCap IG infusions over a median of 162 (101-228) days. There were no study drug-related serious adverse events. The adverse reaction rate was 0.129 per infusion; 97.5% were mild (0.09 per infusion; 28/48) or moderate (0.035 per infusion; 11/48) and 2.5% were severe (0.003; 1/48). 98.5% of the 309 infusions were completed without rate change, interruption, or discontinuation. While 31% (15/48) of subjects experienced a headache at some point, the rate of headaches per infusion rate was 1.8% (15/816 infusions; max. infusion rate 0.08 mL/min). CONCLUSIONS: In the ongoing clinical study, these interim data appear to indicate that PlasmaCap IG is a safe and well tolerated treatment for patients with PIDD. The low rate of adverse reactions may be associated with our unique manufacturing process that minimizes aggregates and other contaminants. RATIONALE: Limited information exists on how to best transition pediatric primary immunodeficiency (PID) patients to adult care. Without a defined and coordinated plan to guide adolescents towards adult services, they can get lost in the health care system. This can lead to poor treatment compliance, clinical deterioration, diminished quality of life, and potentially reduced life expectancy. METHODS: We developed and conducted a needs assessment survey of American Academy of Allergy, Asthma & Immunology (AAAAI) members. The goal was to better understand the characteristics and current practices of providers working with this population as well as the barriers to effective transition. The survey was electronically sent to 20% of eligible AAAAI members (N51250) in Fall 2018. RESULTS: Sixty participants completed the survey (5% response rate), consisting of 34 (57%) internists, 22 (37%) pediatricians, 1 (2%) combined medicine/pediatrics, and 1 (2%) nurse practitioner. Thirty-six (60%) are in a university-affiliated practice. Thirty-five (59%) self-report as taking care of both allergy and PID patients. Only 1 (2%) has a written transition policy and 4 (8%) have a designated staff member to coordinate the transition process. Only 8 (29%) are satisfied with their current transition practices, and 7 (26%) feel adequately trained to address transition. Seventeen (61%) agreed that a consensus statement outlining recommended guidelines would be useful. CONCLUSIONS: This preliminary study revealed that providers are dissatisfied with their current practices and training for transition of care. The majority of participants felt that a consensus statement on transition guidelines would be helpful.
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